Two years of conversations with FDA have led 23andMe back to the health care market with the Oct. 21 launch of its new Personal Genome Service, focused on carrier screening tests. The firm says its close engagement with FDA has improved its customer communication and quality control.
23andMe Inc.has launched a new direct-to-consumer Personal Genome Service about two years after the company was forced off
the health care market by FDA. The firm says its close engagement with FDA during the interim period has improved its customer communication and quality control.